vs
Side-by-side financial comparison of RELMADA THERAPEUTICS, INC. (RLMD) and ScanTech AI Systems Inc. (STAI). Click either name above to swap in a different company.
RELMADA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.3M vs $631.0K, roughly 2.0× ScanTech AI Systems Inc.).
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
RLMD vs STAI — Head-to-Head
Income Statement — Q4 FY2023 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $631.0K |
| Net Profit | — | $-9.7M |
| Gross Margin | — | 27.6% |
| Operating Margin | -2130.6% | -773.2% |
| Net Margin | — | -1532.9% |
| Revenue YoY | 13.0% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.84 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $631.0K | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $346.1K | ||
| Q4 23 | $1.3M | — | ||
| Q3 23 | $1.3M | — | ||
| Q2 23 | $1.4M | — | ||
| Q1 23 | $1.2M | — | ||
| Q4 22 | $1.1M | — |
| Q3 25 | — | $-9.7M | ||
| Q2 25 | — | $-6.9M | ||
| Q1 25 | — | $-17.9M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-22.0M | — | ||
| Q2 23 | $-25.3M | — | ||
| Q1 23 | $-26.3M | — | ||
| Q4 22 | $-37.9M | — |
| Q3 25 | — | 27.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 29.4% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | — | -773.2% | ||
| Q2 25 | — | -440.1% | ||
| Q1 25 | — | -4503.9% | ||
| Q4 23 | -2130.6% | — | ||
| Q3 23 | -1717.3% | — | ||
| Q2 23 | -1908.9% | — | ||
| Q1 23 | -2331.3% | — | ||
| Q4 22 | -3472.5% | — |
| Q3 25 | — | -1532.9% | ||
| Q2 25 | — | -785.1% | ||
| Q1 25 | — | -5174.2% | ||
| Q4 23 | — | — | ||
| Q3 23 | -1665.0% | — | ||
| Q2 23 | -1855.9% | — | ||
| Q1 23 | -2179.6% | — | ||
| Q4 22 | -3404.5% | — |
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 23 | $-0.84 | — | ||
| Q3 23 | $-0.73 | — | ||
| Q2 23 | $-0.84 | — | ||
| Q1 23 | $-0.87 | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.3M | — |
| Total DebtLower is stronger | — | $17.7M |
| Stockholders' EquityBook value | $85.4M | — |
| Total Assets | $97.6M | $5.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 23 | $96.3M | — | ||
| Q3 23 | $106.3M | — | ||
| Q2 23 | $118.5M | — | ||
| Q1 23 | $132.4M | — | ||
| Q4 22 | $148.3M | — |
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $17.7M | ||
| Q1 25 | — | $17.7M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 23 | $85.4M | — | ||
| Q3 23 | $100.7M | — | ||
| Q2 23 | $111.3M | — | ||
| Q1 23 | $125.5M | — | ||
| Q4 22 | $140.4M | — |
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | — | $5.1M | ||
| Q4 23 | $97.6M | — | ||
| Q3 23 | $109.1M | — | ||
| Q2 23 | $122.0M | — | ||
| Q1 23 | $135.6M | — | ||
| Q4 22 | $152.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.2M | $-758.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-758.5K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.2M | ||
| Q4 23 | $-10.2M | — | ||
| Q3 23 | $-11.6M | — | ||
| Q2 23 | $-13.3M | — | ||
| Q1 23 | $-16.5M | — | ||
| Q4 22 | $-35.9M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.2M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | -166.0% | ||
| Q1 25 | — | -623.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.0% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
